Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
33.50    -0.50 (-1.47%)
Bid:
32.00
Ask:
35.00
Spread: 3.00 (9.375%)
Market Cap: £15.60m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Replacement - Director/PDMR Shareholding

29 Sep 2014 12:40

RNS Number : 8666S
Cambridge Cognition Holdings PLC
29 September 2014
 



 

 

The following amendment has been made to the 'Directors/PDMR Shareholding' announcement released on 29 September 2014 at 10.06 under RNS No 8443S. Nick Kerton's total beneficial interest has been corrected to 127,285 Ordinary Shares representing 0.75% of issued share capital of the Company.

 

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Directors/PDMR Shareholding

 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, was notified on 26 September 2014 of the following transactions by Directors.

 

Nick Kerton, Chief Executive Officer, purchased 55,000 ordinary shares at a price of 65.5 pence each. Following this notification, Mr Kerton now has a total beneficial interest of 127,285 Ordinary Shares representing 0.75% of the issued share capital of the Company.

 

Nick Walters, Chief Financial Officer, purchased 45,000 ordinary shares at a price of 65.5 pence each. Following this notification, Mr Walters has a total beneficial interest of 92,000 Ordinary Shares representing 0.54% of the issued share capital of the Company.

 

Cambridge Cognition's capital consists of 16,930,556 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in Treasury.

 

 

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Matthew Robinson/Henrik Persson/Simon Hicks

(Corporate Finance)

Elizabeth Johnson

(Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAFNNADKLEFF
Date   Source Headline
15th Jul 20207:00 amRNSNew virtual study with COVID-19 healthcare workers
3rd Jul 20203:30 pmRNSPosting of Annual Report & Notice of AGM
30th Jun 20209:00 amRNSAnnual Report & Notice of AGM
30th Jun 20207:00 amRNSTrading Update
23rd Jun 20204:18 pmRNSHolding(s) in Company
9th Jun 20207:00 amRNSGrant of Options
5th Jun 20207:00 amRNSCapital Markets Showcase
27th May 20207:00 amRNSOver £1 million of New Contract Wins
6th May 20206:11 pmRNSHolding(s) in Company
6th May 202012:15 pmRNSHolding(s) in Company
5th May 20207:00 amRNSPreliminary Results - Year ended 31 December 2019
29th Apr 20202:19 pmRNSNotice of Results
14th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
23rd Mar 20204:00 pmRNSDelayed Preliminary Results
19th Mar 20207:00 amRNSAward of Innovative Medicines Initiative grant
17th Mar 20207:00 amRNS£1.37 million of new eCOA contracts
10th Mar 20204:15 pmRNSHolding(s) in Company
10th Mar 20204:15 pmRNSHolding(s) in Company
9th Mar 202012:46 pmRNSResult of General Meeting
19th Feb 20207:01 amRNSFundraising to raise £1.4m & Notice of GM
19th Feb 20207:00 amRNSTrading Update and Notice of Results
10th Jan 20203:54 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSCambridge Cognition expands eCOA and wins contract
31st Oct 20194:17 pmRNSGrant of Options
29th Oct 20197:00 amRNSHolding(s) in Company
25th Oct 20197:00 amRNSAlzheimer's drug potential for Cambridge Cognition
26th Sep 201912:15 pmRNSDirector/PDMR Shareholding
23rd Sep 201910:42 amRNSDirector/PDMR Shareholding
19th Sep 20197:00 amRNSInterim Results
30th Aug 20194:59 pmRNSHolding(s) in Company
29th Aug 20192:20 pmRNSHolding(s) in Company
27th Aug 20197:00 amRNSTrading Update
14th Aug 201910:10 amRNSDr. Nick Kerton
12th Aug 20197:00 amRNSExpansion in Chinese market
22nd Jul 20197:00 amRNSNotice of Results
19th Jul 20197:00 amRNSNew Commercial Partnership for NeuroVocalix
1st Jul 20197:00 amRNSAppointment of Non-Executive Director
11th Jun 20197:00 amRNSCapital Markets Day
23rd May 20192:35 pmRNSResult of AGM and Board Changes
1st May 20197:00 amRNSPosting of Annual Report & Notice of AGM
25th Apr 20197:00 amRNSBoard Changes
17th Apr 20197:00 amRNSGrant of Options
19th Mar 20197:00 amRNS£1.3m digital health contract win
14th Mar 20198:54 amRNSHolding(s) in Company
14th Mar 20197:00 amRNSHolding(s) in Company
12th Mar 20195:23 pmRNSDirector/PDMR Shareholding
12th Mar 201911:59 amRNSHolding(s) in Company
7th Mar 20197:02 amRNSAppointment of Chief Operating Officer
7th Mar 20197:01 amRNSFundraising to raise £2.5 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.